Boehringer Ingelheim Press Releases

Boehringer Ingelheim, GWT and the TU Dresden sign diabetes research collaboration

FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adults with Type 2 Diabetes

Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply

Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*

Boehringer Ingelheim significantly expands its supply center for China

Boehringer Ingelheim completes patient entry for Phase III trial
programme in Hepatitis C

Linagliptin demonstrates meaningful improvement in glycaemic control in initial combination therapy with metformin

Winners of the Making More Health Competition Bring Fresh Innovation to Solving Problems in Health

Boehringer Ingelheim and AVEO Pharmaceuticals announce manufacturing agreement for ficlatuzumab

Pradaxa® awarded Prix Galien for most innovative product in Canada

Boehringer Ingelheim race to the finish line in support of World Diabetes Day

New RE-LY® sub-analyses demonstrate safety and efficacy of Pradaxa® (dabigatran etexilate) in patients with heart failure & those undergoing surgery

Thirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" Competition

BI 201335 demonstrates potential to shorten HCV treatment duration while achieving high sustained virological response rates in difficult to treat patients

Hepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment

Boehringer Ingelheim gains approval of extended 4.5 hour time-window for Actilyse® in acute ischaemic stroke for majority of EU countries*

NICE issues Final Appraisal Determination (FAD) with unrestricted recommendation for Pradaxa® (dabigatran etexilate) for patients with non-valvular atrial fibrillation

Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe